BioFilm Pharma and BIOASTER collaborate to accelerate the emergence of a new class of drugs to fight antibiotic resistance and chronic infections

Lyon, France – December 10th, 2019.

BioFilm Pharma (www.biofilmpharma.com) a pharmaceutical company based in Lyon and BIOASTER (www.bioaster.org), the French Institute for Technological Research in Infectious Diseases and Microbiology, announced today the signature of a research contract. To address the challenge of antibiotic resistance, this collaboration will lead to the deciphering of the mode of action of a new class of drugs.

BioFilm Pharma has identified a new generation of antimicrobials that are actives against the bacterial biofilms frequently observed during chronic infections. This partnership will leverage BIOASTER’s scientific expertise and technology platforms, to further boost BioFilm Pharma’s innovative research programs. These joint efforts should accelerate the marketing of first-in-class drugs for the treatment of infected wounds, primarily Diabetic Foot Ulcers and Osteo-Articular Infections. Such infections have a major impact on public health (amputation, reduction in life expectancy) and on health care cost.

This first project aims at identifying the mode of action of non-antibiotic anti-biofilms molecules through an integrated multi-omic analysis. Anti-biofilm candidates of the study have already shown very promising results thanks to the BioFilm Ring Test® technology patented by the BioFilm Technologies group. As of today, this key technology is the only reliable and standardized in vitro biofilm method focusing on bacterial adhesion.

“We are very excited and proud to work with BioFilm Pharma within a project that will contribute to health care innovation. This collaboration will bring together the complementary expertise of both parties to accelerate the development and industrialization of new innovative treatments in the field of infectious diseases and microbiology.” Nathalie GARÇON, CEO&CSO-BIOASTER

“At BioFilm Pharma, we have one goal: to respond to a huge public health problem by targeting chronic wound infections caused by bacterial biofilms where antibiotics are failing. The stakes are high for at-risk populations such as diabetics (4 million in France) and prosthetic wearers (1 million in France). With BIOASTER, we will refine our knowledge on biofilms and accelerate the marketing of these anti-biofilms that we are the only ones to identify. We will renew the antimicrobial arsenal and transform the way to cure infections.” Thierry BERNARDI, CEO, BioFilm Pharma.
ABOUT BIOASTER:

BIOASTER - created in 2012 - is an IRT, Institute of Technological Research, specialized in microbiology and infectiology.

BIOASTER designs, develops and uses transformative technological innovations to meet the needs of industries. Through collaborative public / private projects, it helps to accelerate the development of medical and nutritional solutions with high added value for the benefit of human and animal health.

BIOASTER is involved in four areas of application:
- Antimicrobials: combating antimicrobial resistance
- Vaccines: improving the safety and efficacy of vaccines
- Microbiota: take full advantage of the human and animal microbiota
- Diagnostic: quickly diagnose infections at the bedside

KEY FIGURES:
- 2450m² of laboratories BSL 2 & 3 (LYON & PARIS)
- 100+ collaborators, 80% of whom are scientific experts, 17 different citizenships
- 66 projects including 27 with private partners, 29 with public partners and 10 international and European projects.

More information on www.bioaster.org

ABOUT BIOFILM PHARMA:

Biofilm Pharma was founded in 2017 within the BioFilm Technologies group. BioFilm Pharma benefits from BioFilm Technologies' experience, technological leadership, and patents in its efforts to discover and design the future of antimicrobial drugs. It is now known that serious and chronic infections are caused by bacterial biofilms, a bacterial behavior that promotes surface adhesion, and increases antimicrobial resistance. When it comes to curing infections associated with a biofilm, existing antibiotic treatments are ineffective. BioFilm Pharma has developed an innovative approach, based on products that prevent bacterial adhesion (anti-biofilm) without killing bacteria (non-antibiotic), thus preserving the positive microbiota.

More information on www.biofilmpharma.com/

BioFilm Pharma Contact
Thierry Bernardi - CEO
thierry.bernardi@biofilmpharma.com
Tél.: +33 (0)4 73 33 39 80

BIOASTER Contact
Olivier Charzat, - Head of Communications
olivier.charzat@bioaster.org
Tél.: +33 (0)4 69 84 26 00